ITGB6 (Integrin Subunit Beta 6)

On the basis of our findings, STAT3 and ITGB6 were statistically associated with lymph node metastasis. Thus, we hypothesised that their increased expression can lead to the migration of cancer cells, resulting in lymph node metastasis and affecting overall survival. Further understanding of the signalling pathways mediating STAT3 and ITGB6 may help identify valid therapeutic targets for OSCC patients.

The potent anti-tumor immune response observed both in vitro and in vivo upon ITGB6 inhibition, combined with analysis of RNA-seq data from immune checkpoint blockade-treated patients, encourages the development of ITGB6 blockade and immunotherapy combination regimens. Further pre-clinical studies should facilitate translation of our findings into therapeutic clinical trials for treating immunotherapy-resistant cancers.

The TGFβ-ITGB6 positive feedback axis plays a critical role in liver metastasis of SMAD4 WT PC, highlighting ITGB6 as a potential therapeutic target, especially for patients with intact SMAD4 function.

Our data indicate that PF from PM-PC patients is suitable for transcriptomic analysis. Numerous upregulated mRNAs known to play a role in tumour progression were identified. Our data indicate that mRNA profiling may be a clinically useful tool for further prognostic stratification of patients with proven PM, but larger studies are needed to validate our findings.

ADCs are poised to reshape the therapeutic landscape of NSCLC. Their success will hinge on refining biomarker strategies, managing toxicity, and integrating resistance-mitigating approaches such as bispecific constructs or rational combinations. As research advances, ADCs may become essential components of personalized therapy across a range of molecular and histologic NSCLC subtypes.

We investigated the up- and down-regulation of expression by two predicted potential small molecule regulators (lacidipine and AG879) and four predicted potential gene regulators (AKT2, ITGB6, mir-183, and CD82) through small molecule inhibition, RNA interference, and introduction of microRNAs. The effects of modulation of these regulators were measured on both cell mechanical properties and gene expression in three ovarian cancer cell types. We identified several regulators that change the viscosity and stiffness of the cell with a corresponding change to the functional migratory ability in a cell-type specific manner.

Additionally, through in vitro and in vivo experiments, we demonstrated that ITGB6 promotes HNSCC metastasis by activating the FAK/PI3K/AKT pathway, thereby inhibiting anoikis in DCs. Taken together, these findings suggest a potential therapeutic approach targeting DCs in HNSCC.

In conclusion, this study demonstrates the dual oncolytic and immunogenic potential of an FLT3L-encoding OV, particularly on cDCs. These findings support the further development of this approach as a novel cancer immunotherapy.

An atlas of TAMs was constructed in PC. SPP1 + macrophages drove pancreatic cancer progression via ITGB6-mediated interactions.

High (99%) membranous expression frequency and density on tumor cells underscores the potential of αvβ6-integrin as a theranostic target in ESCC, suggesting that αvβ6-integrin PET/CT imaging may adopt a role in re-staging and therapy guidance in this cancer type. The prolonged tumor retention furthermore indicates a therapeutic potential of αvβ6-integrin targeted radiopharmaceuticals when labeled with radionuclides such as lutetium-177, terbium-161, or actinium-225.

Notably, this tissue-based biomarker panel robustly discriminated precancerous lesion and cervical cancer patients from non-disease controls in a blood-based validation set (30 normal, 25 HSIL and 50 cervical cancer) with an AUC value of 0.9320. This study presents a non-invasive, efficient diagnostic panel for cervical cancer screening.

Furthermore, virtual screening evaluated the upregulated SLC6A14 gene-encoded protein for therapeutic repurposing, revealing promising candidates for PDAC treatment. This study offers exploratory insights into gene expression patterns and molecular biomarkers that may inform future research to improve PDAC prognosis and therapeutic development and provide the repurposed drug candidate for further exploration.